Bristol-Myers Squibb Company(BMY)Company Profile & BusinessNYSE
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.
In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer.
The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Bristol-Myers Squibb Company (BMY) between Aug 1, 2024 and Sep 9, 2026 consists of 64 total transactions. Among these, company executives and board members conducted 60 buys (totaling 912,441 shares) and 4 sells (totaling 36,749 shares). This activity resulted in a net change of 875,692 shares, reflecting net buying interest with an estimated net acquisitions value of $48.75M.
64 insider transactions found. Showing 10 of 64 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| MASSACESI CRISTIAN | Officer | 6,249 | $0.40 | Sep 9, 2026 |
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | -6,249 | $64.57 | Sep 9, 2026 |
| SHORT BARTIE WENDY | Officer | 1,236 | $0.08 | Sep 1, 2026 |
| HOLZER PHIL M | Officer | 500 | $33750.00 | Aug 25, 2026 |
| Holzer Phil M | SVP and Controller | -500 | $67.50 | Aug 25, 2026 |
| MASSACESI CRISTIAN | Officer | 51,172 | N/A | Jul 31, 2026 |
| GALLMAN CARI | General Counsel | 1,061 | N/A | Jul 31, 2026 |
| HALLER JULIA A | Director | 20,460 | $1.10 | Jun 15, 2026 |
| SHORT BARTIE WENDY | Officer | 8,040 | N/A | Jun 3, 2026 |
| LENKOWSKY ADAM | Officer | 1,373 | N/A | May 1, 2026 |
Explore More Analysis for BMY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.